Anadis to supply nutraceutical to Chinese military
19 May, 2004 by Graeme O'NeillMelbourne biotech Anadis Limited (ASX:ANX) has announced the first sale to China of its bovine colostrum-based nutraceutical – a 3-tonne consignment destined to be used as a health food by the Chinese military and other agencies, to build immunity to enteric diseases.
New BIF funding up for grabs
17 May, 2004 by Renate KrelleAn undisclosed amount of new funding will be made available under the sixth round of the federal Biotechnology Innovation Fund (BIF), newly rebadged as part of the $1 billion, five-year Commercial Ready program.
Dynamic Hearing licenses software to Germany’s Interton
17 May, 2004 by Melissa TrudingerHearing aid software developer Dynamic Hearing has entered into a licensing agreement with German hearing aid manufacturer Interton Hoergeraete.
Cryptome lures expat home for advisory role
14 May, 2004 by Renate KrelleMelbourne-based proteomics researcher Cryptome Pharmaceuticals has lured Dr Paul Cossum, an Australian who for the last 20 years has worked in American biopharmas, to join the company. As a scientific consultant, Cossum will provide advice on drug development and regulatory affairs.
PanBio to raise $7 million to speed products to market
13 May, 2004 by Melissa TrudingerDiagnostics company Panbio (ASX: PBO) has raised AUD$3 million in a placement to existing and new shareholders at a price of $0.42 per share, and plans to raise a further $4.2 million through a share purchase plan to existing shareholders at the same price.
Monsanto drops Australian GM canola program
12 May, 2004 by Graeme O'NeillMonsanto Australia will make no further investment in efforts to commercialise its genetically modified (GM) herbicide-tolerant Roundup Ready canola in Australia for at least 12 months.
VRI launches probiotics into pharmacies
12 May, 2004 by Renate KrelleVRI BioMedical announced today that its probiotics range for the treatment of irritable bowel syndrome, diarrhoea and general intestinal health, is due to hit pharmacy shelves.
Novogen to begin trials with phenoxodiol-derivative
12 May, 2004 by Melissa TrudingerNovogen (ASX: NRT) has been approved to commence a Phase I clinical trial at Sydney's St George Hospital of its second anti-cancer drug NV-18, a derivative of the company's first generation drug phenoxodiol.
Abbott resolution translates to profit for Peptech
11 May, 2004 by Graeme O'NeillSydney-based biotech Peptech (ASX:PTD) is enjoying halcyon days, today revealing an after-tax profit of AUD$29.5 million for the half-year to March 31, on total revenues of $45.5 million.
Biota sues GSK for lost Relenza revenues
05 May, 2004 by Renate Krelle and Melissa TrudingerVictorian drug-developer Biota released a bombshell this morning, announcing that it was suing its marketing partner, UK-based GlaxoSmithKline (GSK), for failure to promote and support its influenza drug, Relenza in the 5 years since the drug was launched.
Norwood Immunology set for May IPO in London
05 May, 2004 by ReutersAustralian biotech company Norwood Immunology plans to list its shares in London in late May, which should value the company at about £115 million (AUD$283 million).
Avastra plans $8 million IPO for BioWeld
05 May, 2004 by Renate KrelleSydney-based biotechnology company Avastra has announced it will open its $8 million share offer this Friday. Avastra will offer eight million shares at $1 per share, equivalent to 29 per cent of the company. Managing Director Paul Ralph said that with oversubscriptions this may rise to 33 per cent.
Progen anti-cancer compound earns orphan drug status
04 May, 2004 by Iain ScottBrisbane-based Progen (ASX:PGL) has earned 'orphan drug' status from the US Food and Drug Administration for its much-touted PI-88 compound, for treatment of malignant melanoma.
Genetic Solutions finds partner for US, Canadian market
03 May, 2004 by Graeme O'NeillBrisbane biotech Genetic Solutions is set to create a tidal wave in the international beef industry's gene pool, after licensing its GeneStar DNA markers to new US partner Bovigen Solutions.
Meditech chairman, CEO resign at AGM
30 April, 2004 by Melissa TrudingerBiotech veteran Bob Moses, the chairman of Melbourne biotech company Meditech (ASX:MTR), had harsh words yesterday for the shareholders whose lack of support for the re-election of CEO Chris Carter as a director on the board led to both he and Carter resigning their positions.
